{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BAYRY/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":7.59,"timestamp":1749240000000,"preClose":7.521,"halted":0,"volume":837032,"hourTrading":{"tag":"盘前","latestPrice":7.6346,"preClose":7.59,"latestTime":"08:39 EDT","volume":124179,"amount":947870.36,"timestamp":1749472766641},"delay":15,"floatShares":3929259738,"shares":3929696328,"eps":-0.897103,"marketStatus":"Pre-Mkt","change":0.069,"latestTime":"06-06 16:00:00 EDT Delay","open":7.48,"high":7.6,"low":7.46,"amount":6313842.425099995,"amplitude":0.018615,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.897103,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1749475800000},"marketStatusCode":1,"adr":0,"adrRate":0.25,"exchange":"OTCQX","adjPreClose":7.59,"volumeRatio":1.614050378597038},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"2.55%","roe":"-9.49%","lyrEps":-0.672343,"volumeRatio":1.614050378597038,"shares":3929696328,"dividePrice":0.031342,"high":7.6,"amplitude":0.018615,"preClose":7.521,"low":7.46,"week52Low":4.79,"pbRate":"0.81","psRate":"0.56","week52High":8.58,"institutionHeld":0,"latestPrice":7.59,"eps":-0.897103,"divideRate":0.004129,"volume":837032,"delay":15,"ttmEps":-0.897103,"open":7.48,"prevYearClose":4.88,"prevWeekClose":7.59,"prevMonthClose":7.07,"prevQuarterClose":6.02,"fiveDayClose":7.07,"twentyDayClose":6.64,"sixtyDayClose":6.26},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2503589293","title":"Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?","url":"https://stock-news.laohu8.com/highlight/detail?id=2503589293","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503589293?lang=en_us&edition=fundamental","pubTime":"2025-01-13 21:22","pubTimestamp":1736774520,"startTime":"0","endTime":"0","summary":"Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 35.6% in the past six months compared with the industry’s decline of 12.3%.The stock has underperformed the sector and the S&P 500 Index during this timeframe. Eylea’s dismal performance in an increasingly competitive environment has dampened investors’ sentiment.Eylea’s Sales Decline Hampers REGN Ophthalmology Unit. Lead drug Eylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications. Eylea sales have boosted the company’s top line for many years. However, Eylea’s sales have been under pressure in the last couple of years due to competition from Roche’s RHHBY Vabysmo.To counter the decline in Eylea sales, Regeneron developed a higher dose of the drug. While the initial uptake of Eylea HD was encouraging as Eylea patients transitioned to the higher dose, it now seems Eylea HD will take some time to offset the rapid erosion in Eylea sales.The company also has other arrows in its","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-stock-plunges-35-6-132200313.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4121","IE00BFXG1179.USD","BK4530","BK4581","LU1571399168.USD","BK4585","CRL","LU0058720904.USD","IE00B2B36J28.USD","IE0002141913.USD","IE00BFTCPJ56.SGD","LU0053666078.USD","LU0882574055.USD","LU2362541513.USD","IE00BJJMRZ35.SGD","LU1983299246.USD","LU2089984988.USD","BK4566","LU0823416689.USD","REGN","BK4139","LU2237438978.USD","LU0109394709.USD","LU2106854487.HKD","LU2242646821.SGD","BK4533","AMGN","BK4534","LU1061106388.HKD","LU0889565916.HKD","SNY","LU0390134368.USD","LU1974910355.USD","LU1917777945.USD","LU0868494617.USD","03165","LU1057294990.SGD","RHHBY","LU0114720955.EUR","IE0009355771.USD","LU2023250504.SGD","BK4007","LU2242652126.USD","SG9999001440.SGD","FL","IE00BJT1NW94.SGD","LU0289739699.SGD","IE00B4R5TH58.HKD","LU2362541273.HKD","BAYRY"],"gpt_icon":0},{"id":"2502689158","title":"Bayer: Gadoquatrane met primary, secondary endpoints in Phase III QUANTI studies","url":"https://stock-news.laohu8.com/highlight/detail?id=2502689158","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502689158?lang=en_us&edition=fundamental","pubTime":"2025-01-11 00:30","pubTimestamp":1736526643,"startTime":"0","endTime":"0","summary":"Bayer (BAYRY) announced topline results of the pivotal Phase III QUANTI studies evaluating the efficacy and safety of gadoquatrane, an investigatio...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/bayer-gadoquatrane-met-primary-secondary-endpoints-in-phase-iii-quanti-studies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/bayer-gadoquatrane-met-primary-secondary-endpoints-in-phase-iii-quanti-studies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4134","III","BAYRY","BK4007"],"gpt_icon":0},{"id":"2500311189","title":"Bayer Secures End of Roundup Weedkiller Litigation in Australia -- Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2500311189","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500311189?lang=en_us&edition=fundamental","pubTime":"2025-01-03 22:17","pubTimestamp":1735913820,"startTime":"0","endTime":"0","summary":"Bayer said the Federal Court of Australia closed the last pending case in the country over whether its Roundup weedkiller causes cancer, a win for the German pharmaceutical and agricultural conglomerate that still faces litigation in the U.S.The group has been hounded by lawsuits since 2018 when it closed the $63 billion acquisition of Monsanto, which developed Roundup. Critics have argued that glyphosate, the active ingredient found in Roundup, causes cancer though Bayer has long maintained that glyphosate is safe to use.The Federal Court of Australia has now discontinued the last pending case in the country. The decision builds on an earlier case that Bayer won in the same court, where judges issued a 322-page ruling saying the weight of scientific evidence didn't support a link between glyphosate and non-Hodgkin lymphoma, a type of cancer.Bayer said the outcome was consistent with global regulatory and scientific assessments that glyphosate isn't carcinogenic, including from the Aus","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"2492136717","title":"REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2492136717","media":"Zacks","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492136717?lang=en_us&edition=fundamental","pubTime":"2024-12-18 23:17","pubTimestamp":1734535020,"startTime":"0","endTime":"0","summary":"Eylea is Regeneron’s blockbuster eye disease drug, which is already approved for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and RVO.The FDA has also approved Eylea to treat preterm infants with retinopathy of prematurity as well. Eylea HD is a high-dose version of Eylea.In the past three months, shares of REGN have plunged 35.7% compared with the industry’s 10.8% decline.Additionally, about 90% of Eylea HD patients were able to maintain eight-week dosing intervals through the 36-week treatment period. In the QUASAR study, Eylea HD demonstrated a safety profile comparable to that of Eylea. Additionally, it aligned with the established safety profile of Eylea HD observed in previous pivotal studies.Please note that Bayer’s BAYRY HealthCare unit co-develops Eylea withRegeneron. REGN records net product sales of Eylea in the United States. Bayer records net product sales of Eylea outside the United States. Regeneron records its share of profits/losse","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/X5f0KWUqd43xLwLZQjf2Jw--~B/aD0zOTI7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/83114bcf5a91754ed7ae3f6080390cd9","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/X5f0KWUqd43xLwLZQjf2Jw--~B/aD0zOTI7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/83114bcf5a91754ed7ae3f6080390cd9"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regns-eylea-hd-shows-non-151700259.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4581","SPRO","IE00B1XK9C88.USD","SG9999001440.SGD","IE00BKVL7J92.USD","LU0114720955.EUR","LU2362541273.HKD","LU0942090050.USD","BK4550","LU1496350502.SGD","LU0943347566.SGD","IE00BSNM7G36.USD","LU0823434583.USD","LU1162221912.USD","LU1914381329.SGD","REGN","LU0689472784.USD","LU0882574055.USD","LU1778281490.HKD","LU0079474960.USD","LU0320765646.SGD","LU1929549753.HKD","LU0820561818.USD","LU0058720904.USD","IE00BWXC8680.SGD","LU0823416689.USD","LU2089984988.USD","LU2362541513.USD","LU2468319806.SGD","LU1093756325.SGD","LU1551013342.USD","BK4566","HD","LU1674673691.USD","BK4504","LU1093756168.USD","LU2362540622.SGD","LU0354030438.USD","LU1674673428.USD","CSTL","BK4567","BAYRY","LU0868494617.USD","BK4196","BK4533","LU0868494708.USD","LU1989772923.USD","LU2023250504.SGD","LU0823411888.USD","LU0234572021.USD"],"gpt_icon":0},{"id":"2491537198","title":"Regeneron Down 15.5% Year to Date: How to Play the Stock?","url":"https://stock-news.laohu8.com/highlight/detail?id=2491537198","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491537198?lang=en_us&edition=fundamental","pubTime":"2024-12-13 22:09","pubTimestamp":1734098940,"startTime":"0","endTime":"0","summary":"Shares of Regeneron Pharmaceuticals, Inc. REGN have dropped 15.5% in the year so far compared with the industry’s decline of 6.3%.The stock has underperformed the sector and the S&P 500 Index during this timeframe. While the stock’s performance was encouraging at the onset of 2024, challenges for lead drug Eylea have dampened investors’ sentiment of late.Eylea is an anti-vascular endothelial growth factor inhibitor approved for various ophthalmology indications.Regeneron has a collaboration agreement with Bayer BAYRY for Eylea. Regeneron records the net product sales of Eylea and Eylea HD in the United States, and Bayer records its net product sales outside the country. Regeneron records its share of profits in connection with Eylea’s sales outside the United States.REGN’s oncology franchise got a boost with the European Commission's approval of odronextamab for treating adult patients with relapsed or refractory (R/R) follicular lymphoma  or R/R diffuse large B-cell lymphoma after two","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0.VF5p.GUKhgU24gMni2XA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/59a827b8514d5d6d47690daa5eb16f24"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/regeneron-down-15-5-date-140900718.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["RHHBY","BK4530","REGN","LU2106854487.HKD","LU0823416689.USD","03165","LU0058720904.USD","LU0390134368.USD","BAYRY","BK4094","LU0882574055.USD","LU1974910355.USD","CRL","LU0289739699.SGD","LU0889565916.HKD","SNY","BK4585","LU0053666078.USD","LU2468319806.SGD","BK4121","LU0320765992.SGD","LU2362541513.USD","FL","BK4007","LU2362540622.SGD","LU0109394709.USD","BK4139","LU2023250504.SGD","LU2089984988.USD","IE00BFXG1179.USD","LU0114720955.EUR","BK4588","LU1917777945.USD","LU2362541273.HKD"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":4,"totalSize":65,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"date":"2025-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1754467200000,"name":null,"time":"","dateTimestamp":1754452800000,"actualEps":null},{"market":"US","date":"2025-05-13","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"","actualEps":null},{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"date":"2024-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722974400000,"name":null,"time":"Post Market","dateTimestamp":1722916800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2016-04-27","recordDate":"2016-04-29","paymentDate":"2016-05-12","value":2.091196,"currency":"USD"},{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"},{"executeDate":"2022-05-02","recordDate":"2022-05-03","paymentDate":"2022-05-16","value":0.549114,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":2,"updateTime":1746244800000}}}